本帖最后由 老马 于 2012-1-13 21:20 编辑
6 C2 r; a) K `# M* @3 `/ [* ?. Z. V2 F$ s
爱必妥和阿瓦斯丁的比较
5 V' C3 L& O' J6 |: {
3 K; [/ T& @. d3 f: x) mhttp://cancergrace.org/lung/2008/08/30/bms099-os-neg/! N7 p# k; a' R: r, K. ^
) |0 C/ a0 W, d) X
( ]* E; d, ^# X0 h
http://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/% \) `, i6 `0 W/ a4 G& ?
==================================================
" I' \3 y; y h' c4 y ? }) qOverall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)
. W, v; f" ~$ L$ O% G- m$ `Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.
N0 j0 ]1 V" G! `* Y/ ^) uResults: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (～62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported., d; `. m& _1 z
|
显身卡
' ` `4 U3 s4 }5 K% i4 `4 x3 E" i5 g
